Drug Candidate for Treatment of Pain

APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate that Arena is exploring for potential development in several indications, including pain. This compound, through its selectivity, is designed to provide pain relief without psychotropic effects and without the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in several animal models of pain.


We have completed a randomized, double-blind and placebo-controlled Phase 1b clinical trial to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD371.

Drug Candidate Disease Area Target Status Retained Rights
APD371 Pain CB2 Agonist Phase 1 Program Completed Worldwide

Drug Candidate APD371
Disease Area Pain
Target CB2 Agonist
Status Phase 1 Program Completed
Retained Rights Worldwide

APD371 has not been approved by the US Food and Drug Administration or any other regulatory agency.